logo
ResearchBunny Logo
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Medicine and Health

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Y. Li, Y. Cong, et al.

Exciting advancements in cancer therapy are on the horizon! This study by Ying Li and colleagues reveals that an innovative IL-21-anti-PD-1 antibody fusion protein significantly enhances memory T cell generation and boosts antitumor effects in mice, surpassing traditional PD-1 blockade methods. Discover how this could reshape immune checkpoint therapies!

00:00
00:00
Playback language: English
Abstract
PD-1 blockade, a promising cancer therapy, only benefits a minority of patients. This study demonstrates that targeting IL-21 to tumor-reactive T cells using an IL-21-anti-PD-1 antibody fusion protein (PD-1Ab21) enhances memory T cell generation and antitumor effects in mice. PD-1Ab21 was superior to combined PD-1 blockade and IL-21 infusion, suggesting a potential strategy to improve immune checkpoint blockade therapy.
Publisher
Nature Communications
Published On
Feb 01, 2021
Authors
Ying Li, Yanni Cong, Mingming Jia, Qianian He, Haiqing Zhong, Yun Zhao, Hang Li, Meining Yan, Jia You, Jia Liu, Lieping Chen, Haiying Hang, Shengdan Wang
Tags
PD-1 blockade
IL-21
antitumor therapy
T cells
immune checkpoint
cancer therapy

Related Publications

Explore these studies to deepen your understanding of the subject.

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Medicine and Health

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML

D. Nixdorf, M. Sponheimer, et al.

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
Medicine and Health

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models

H. Shi, A. Li, et al.

Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Medicine and Health

Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

C. E. Brown, J. C. Hibbard, et al.

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
Medicine and Health

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy

C. Gonzalez, S. Williamson, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny